Conference Coverage
Conference Coverage
Chemo-free induction regimen shines in MCL
SAN DIEGO – A chemotherapy-free induction regimen of ibrutinib and rituximab was well tolerated and achieved an overall response rate of 100%...
Conference Coverage
Lenalidomide maintenance extended progression-free survival in high-risk CLL
SAN DIEGO - Lenalidomide maintenance may be an option for patients with chronic lymphocytic leukemia at risk of early progression.
Conference Coverage
Rituximab vanquished MRD in mantle cell lymphoma
SAN DIEGO – Rituximab can at least temporarily vanquish minimal residual disease in mantle cell lymphoma patients who relapse after induction...
Conference Coverage
Ibrutinib continues to wow in CLL/SLL
SAN DIEGO – More than 90% of the first patients with previously untreated chronic lymphocytic leukemia who received ibrutinib in an early study...
Conference Coverage
Combined checkpoint blockade promising in HL
SAN DIEGO—Immune checkpoint blockade with nivolumab plus ipilimumab has shown promise in treating hematologic malignancies, particularly classical...
Conference Coverage
CAR met primary endpoint at interim analysis in DLBCL
2016 ASH Annual Meeting SAN DIEGO—The chimeric antigen receptor (CAR) T-cell therapy KTE-C19 has met its primary endpoint at the pre-specified...
Conference Coverage
Lenalidomide improves PFS after 1st and 2nd line CLL therapy
SAN DIEGO – Lenalidomide, a mainstay of maintenance therapy for multiple myeloma, is now making inroads into maintenance therapy following first-...
Conference Coverage
VIDEO: Obinutuzumab bests rituximab for PFS in follicular lymphoma
SAN DIEGO – For patients with indolent non-Hodgkin lymphoma, adding rituximab to a standard-combination chemotherapy regimen resulted in...
Conference Coverage
Antibody face-off in follicular lymphoma gives PFS, but not OS, edge to obinutuzumab
SAN DIEGO – Obinutuzumab, a second-generation anti-CD20 antibody touted as the heir apparent to rituximab, offered a PFS edge over rituximab when...
Conference Coverage
Idelalisib held unlikely to become frontline therapy for CLL
Safety issues with idelalisib, a first-in-class PI3K delta inhibitor, are an important concern in patients with chronic lymphocytic leukemia–...